Vineet Laboratories enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


69.3	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
16.7	16.7	0.3	0.2	0.6
45.3	45.3	40.0	44.3	31.1
97.9	—	—	—	—
28.6	28.6	39.7	44.1	30.5
₹50.96	—	—	—	—

90.9	90.9	54.7	79.0	64.8
49.8%	49.8%	73.2%	56.1%	48.0%
0.46×	—	—	—	—

1.57×	—	—	—	—
9.40×	—	—	—	—
12.21×	—	—	—	—
62.4	59.4	75.0	151	212
10.4	8.5	−16.3	7.2	7.7
8.0	6.1	−18.8	4.7	5.3
—	−12.2	11.5	−11.4	−9.6
−13.4	−13.4	10.4	−11.7	−17.3
—	−14.1	10.3	−11.7	−18.5
—	1.2	1.0	0.2	7.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

VINEETLAB₹36.06

Vineet Laboratories Limited

· Pharma & Health

₹ CrorePeersBIOFILCHEM MANGALAM LASA KREBSBIO ALPA BALPHARMA ORTINGLOBE NATCAPSUQMcap ₹69.3 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	69.3
- Cash, Equiv & ST Investments	0.6	0.2	0.3	16.7	16.7
+ Total Debt	31.1	44.3	40.0	45.3	45.3
Enterprise Value	—	—	—	—	97.9
Net Debt (memo)	30.5	44.1	39.7	28.6	28.6
EV per Share	—	—	—	—	50.96

Total Capital	64.8	79.0	54.7	90.9	90.9
Total Debt/Total Capital	48.00	56.06	73.22	49.85	49.85
Total Debt/EV	—	—	—	—	0.46

EV/Sales	—	—	—	—	1.57
EV/EBITDA	—	—	—	—	9.40
EV/EBIT	—	—	—	—	12.21
Reference Items — Trailing FY Values
Sales	212.3	150.6	75.0	59.4	62.4
EBITDA	7.7	7.2	-16.3	8.5	10.4
EBIT	5.3	4.7	-18.8	6.1	8.0
Operating Cash Flow	-9.6	-11.4	11.5	-12.2	—
Free Cash Flow	-17.3	-11.7	10.4	-13.4	-13.4
FCFF (free cash flow to the firm)	-18.5	-11.7	10.3	-14.1	—
Capital Expenditure	7.6	0.2	1.0	1.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.